Merit Medical Systems, Inc. (MMSI) Stock Analysis: 18.84% Potential Upside Beckons Investors
Merit Medical Systems, Inc. (MMSI), a healthcare sector player with a $5.1 billion market cap, shows strong operational performance with 9.50% revenue growth and an EPS of 2.43. Analysts are largely positive, with a consensus target price of $101.45, suggesting an 18.84% upside. The company's focus on reinvesting earnings for growth, coupled with its global presence and diversified product portfolio, makes it an attractive opportunity for growth-oriented investors.
MMSI PE Ratio & Valuation, Is MMSI Overvalued
Merit Medical Systems Inc (MMSI) is currently considered undervalued, with a forward PE ratio of 18.69 compared to its five-year average of 24.34. Its fair price is estimated to be between $96.51 and $121.84, making it undervalued by 11.54% relative to its current price of $85.37. While its P/S ratio of 2.94 is slightly above the industry average of 2.90, this premium may be unsustainable given its 9.51% revenue growth.
MMSI PE Ratio & Valuation, Is MMSI Overvalued
Merit Medical Systems Inc (MMSI) is currently considered undervalued, with a forward PE ratio of 18.73, which is lower than its five-year average of 24.36. The fair price for MMSI is estimated to be between $96.25 and $121.55, suggesting it is undervalued by 11.2% compared to its current price of $85.47. Despite a P/S ratio that is -10% above the industry average, its robust revenue growth of 9.51% is noted, though the premium is deemed unsustainable.
Merit Medical at Wells Fargo conference: strategic review deepens By Investing.com
Merit Medical Systems Inc. discussed its ongoing strategic review and long-term growth plans at the Wells Fargo 21st Annual Healthcare Conference. The company reported strong Q2 growth, raised full-year guidance, and is evaluating eight platforms for potential changes and product rationalization, emphasizing "evolution, not revolution." CEO Martha Aronson highlighted core competencies, customer focus, and optimism for growth in areas like oncology, embolics, and a continued commitment to the China market despite challenges.
Merit Medical to Participate in Upcoming Investors Conferences in September
Merit Medical Systems, Inc. announced its participation in several investor conferences in September 2026. Management will attend the Wells Fargo 2026 Healthcare Conference, the Baird 2026 Global Healthcare Conference, the 19th Annual Barrington Research Virtual Fall Investment Conference, and the Sidoti Small Cap Conference. Live audio webcasts and replays of relevant sessions will be available on the company's investor relations website.
Merit Medical to Participate in Upcoming Investors Conferences in September
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced its participation in several investor conferences in September 2026, including the Wells Fargo, Baird, Barrington Research, and Sidoti conferences. Management will engage in fireside chats, presentations, and one-on-one meetings. Live audio webcasts and replays will be available on the company's investor relations website.
Merit Medical Systems (NASDAQ: MMSI) Appoints Lewis Sheri as EVP of Global Operations, Announces Initial Insider Stake
Merit Medical Systems (NASDAQ: MMSI) has appointed Lewis Sheri as Executive Vice President of Global Operations. This appointment also includes Sheri's initial insider stake in the company, as confirmed by a recent Form 3 filing. This move introduces a new senior operational leader to the company's global operations.
The Technical Signals Behind (MMSI) That Institutions Follow
Stock Traders Daily provides a technical analysis of Merit Medical Systems Inc. (NASDAQ: MMSI), indicating neutral readings in shorter horizons and potential easing of a long-term weak bias. The analysis includes AI-generated trading strategies for different risk profiles, along with multi-timeframe signal analysis detailing support and resistance levels.
Merit Medical Systems (MMSI) Names New Operations Chief As Fair Value Stays In Focus
Merit Medical Systems (MMSI) has appointed Sheri Lewis as Executive Vice President of Global Operations, a change that could impact the company's efficiency, cost management, and resilience. Despite the company's recent strong share price performance and trading at a discount to fair value estimates, investors are considering potential risks like reimbursement delays and higher operating costs. The market currently views MMSI as 9.6% undervalued, with a fair value of $100.27 driven by expectations of improved margins and cash flow.
Merit Medical Systems (MMSI) COO Neil Peterson Sells 7,500 Shares
Merit Medical Systems' COO, Neil Peterson, sold 7,500 shares of MMSI for approximately $678,375. This transaction is part of a broader trend of insider selling at the company over the past year, with 33,949 shares sold and no purchases by Peterson. The stock is currently trading near its intrinsic value based on GuruFocus's GF Value, suggesting it is fairly valued.
Merit Medical COO Neil W. Peterson Sells 7,500 Shares at $90.45 Average Price
Merit Medical Systems Inc.'s COO, Neil W. Peterson, sold 7,500 common stock shares on August 24, 2026, at an average price of $90.448 per share. Following this transaction, Peterson directly holds 18,051 common stock shares and also possesses significant non-qualified stock options. The sale details were disclosed in a Form 4 filed on August 25, 2026.
Merit Medical Systems Chief Operating Officer Sold Shares Worth Over $678K
Merit Medical Systems' Chief Operating Officer, Neil W. Peterson, sold 7,500 shares of the company stock for a total of $678,360. The shares were sold at a weighted average price of $90.448 per share, with individual transaction prices ranging from $90.43 to $90.53. Following this transaction, Peterson directly owns 18,051 shares.
Merit Medical (NASDAQ: MMSI) COO sells 7,500 shares at $90.448
Merit Medical Systems Inc. (MMSI) Chief Operating Officer Neil W. Peterson sold 7,500 shares of common stock at a weighted average price of $90.448 per share on August 24, 2026. Following this transaction, Peterson directly holds 18,051 common shares and also possesses non-qualified stock options for an additional 38,576 shares. The sale, reported in a Form 4 filing, involved multiple transactions with prices ranging from $90.43 to $90.53.
Merit Medical (NASDAQ: MMSI) HR chief gifts 650 shares
Michel J. Voigt, Chief Human Resources Officer of Merit Medical (NASDAQ: MMSI), reported a charitable gift of 650 common shares on August 24, 2026. Following this transaction, Voigt directly holds 45,412 common shares and 2,265 shares indirectly through a 401(k) plan, in addition to non-qualified stock options. This Form 4 filing indicates a neutral impact and sentiment regarding the transaction.
Merit Medical (NASDAQ: MMSI) officer plans another stock sale
An officer at Merit Medical Systems, Inc. (NASDAQ: MMSI), Neil W. Peterson, has filed a Form 144 indicating an intent to sell 7,500 shares of common stock with an aggregate market value of $678,360.00. The shares were acquired on March 6, 2024, through the exercise of options for cash, and the proposed sale date is August 24, 2026. This filing follows previous sales by Peterson totaling 21,449 shares worth $1,823,165.00 within the last three months.
Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?
Merit Medical Systems, Inc. (MMSI) shares have risen 22.2% in the past month, supported by strong Q2 2026 results including accelerated revenue growth, an earnings beat, and a raised 2026 outlook. Despite trading at a premium to its sub-industry valuation, fundamental support from organic growth and margin improvements, along with positive estimate revisions, suggest potential for further gains, though tariff exposure and competitive pressures remain challenges. The company's therapeutic mix is accelerating, but significant competition and valuation concerns warrant a balanced short-term view.
Trillium Asset Management LLC Makes New $6.11 Million Investment in Merit Medical Systems, Inc. $MMSI
Trillium Asset Management LLC has made a new investment of $6.11 million in Merit Medical Systems, Inc. (NASDAQ:MMSI), acquiring 88,038 shares. This purchase represents a 0.15% stake in the medical instruments supplier, with institutional investors now owning 99.66% of the company. Merit Medical recently reported strong quarterly earnings, exceeding revenue and EPS estimates, and analysts maintain a "Moderate Buy" consensus rating for the stock.
Merit Medical names Sheri Lewis as global operations chief
Merit Medical Systems, Inc. announced the appointment of Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience in global operations and supply chain management from previous roles at companies like Medtronic and Honeywell. This appointment follows the transition of current COO, Neil Peterson, to a Senior Advisor role as he prepares for retirement in March 2027.
Merit Medical names Sheri Lewis as global operations chief
Merit Medical Systems, Inc. announced the appointment of Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience in global operations, manufacturing, and supply chain management. The current Chief Operating Officer, Neil Peterson, will transition to a Senior Advisor role before completing over 32 years of service with the company on March 5, 2027.
How Merit’s Leadership Transition in Global Operations at Merit Medical Systems (MMSI) Has Changed Its Investment Story
Merit Medical Systems (MMSI) recently appointed Sheri Lewis as Executive Vice President of Global Operations, bringing extensive experience to the role. This leadership change is expected to support operational execution and supply chain resilience, rather than immediately altering the investment narrative around key risks like tariffs or reimbursement. Investors will be watching how her expertise helps the company meet its raised 2026 revenue guidance while navigating ongoing challenges.
Merit Medical names Sheri Lewis as global operations chief By Investing.com
Merit Medical Systems, Inc. announced the appointment of Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience from various leadership roles in global operations, manufacturing, and supply chain management at companies like SkinHealth Systems, Avantor, Medtronic, and Honeywell. She will succeed current Chief Operating Officer Neil Peterson, who will transition to a Senior Advisor role until March 5, 2027, concluding over 32 years of service with the company.
Merit Medical names Sheri Lewis as global operations chief By Investing.com
Merit Medical Systems, Inc. (NASDAQ:MMSI) has appointed Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience from previous senior roles at companies like Medtronic and Honeywell. This appointment follows current COO Neil Peterson's transition to a Senior Advisor role before his retirement in March 2027.
Merit Medical Announces Global Operations Leadership Transition
Merit Medical Systems, Inc. announced that Sheri Lewis will join as Executive Vice President of Global Operations, effective August 31, 2026. Ms. Lewis brings three decades of experience in global operations, manufacturing, and supply chain management from various senior roles. Neil Peterson, the current Chief Operating Officer, will transition to a Senior Advisor role to ensure a smooth handover and will complete his 32 years of service to Merit in March 2027.
After more than 32 years, Merit Medical's chief operating officer will become a senior adviser
Merit Medical Systems (NASDAQ: MMSI) has announced a leadership transition in its global operations. Sheri Lewis will join as Executive Vice President of Global Operations, bringing 30 years of experience, while current COO Neil Peterson will transition to Senior Advisor before concluding his 32-year tenure with the company. This move aims to support continuity and strategic growth.
Merit Medical Announces Global Operations Leadership Transition
Merit Medical Systems, Inc. announced that Sheri Lewis will join the company as Executive Vice President of Global Operations, effective August 31, 2026. Ms. Lewis brings extensive experience from previous senior roles in global operations, manufacturing, and supply chain management. Neil Peterson, current Chief Operating Officer, will transition to a Senior Advisor role to ensure a smooth handover before completing his 32-year tenure with Merit Medical on March 5, 2027.
How Merit’s Leadership Transition in Global Operations at Merit Medical Systems (MMSI) Has Changed Its Investment Story
Merit Medical Systems recently appointed Sheri Lewis as Executive Vice President of Global Operations, bringing 30 years of experience to the role. This leadership change is expected to support operational execution and supply chain resilience, rather than immediately altering the investment narrative concerning reimbursement or tariffs. Investors will be observing how her expertise helps Merit Medical maintain its recently raised 2026 revenue guidance amidst ongoing challenges.
Merit Medical Systems, Inc. (MMSI) Stock Analysis: A Promising 10.48% Upside For Investors
Merit Medical Systems, Inc. (MMSI) presents a compelling investment opportunity in the healthcare sector, boasting a market capitalization of $5.42 billion and strong financial performance with 9.50% revenue growth and an EPS of 2.43. Analysts show high confidence with an average target price of $100.27, suggesting a 10.48% upside. Despite technical indicators showing the stock as overbought, positive MACD suggests continued investor interest, further supported by the company's diverse product portfolio and strategic market reach.
Merit Medical Systems Eyes New Long-Range Plan as Growth, Margins Gain Momentum
Merit Medical Systems (MMSI) is developing a new long-range plan under its new CEO, Martha, focusing on a reorganized reporting structure with Foundational and Therapeutic product categories. The company is seeing strong momentum in revenue growth and margin expansion, with a focus on strategic acquisitions that deepen existing platforms. Merit's CFO, Raul Parra, indicated that the new plan will likely be announced with Q4 earnings and will continue to prioritize revenue growth, operating margin expansion, and free cash flow while seeking further margin improvements.
Merit Medical Systems Eyes New Long-Range Plan as Growth, Margins Gain Momentum
Merit Medical Systems (MMSI) is developing a new long-range plan, building on recent revenue and margin growth under new CEO Martha. The company has reorganized its reporting structure into Foundational and Therapeutic product categories and is focusing on disciplined M&A to deepen existing market positions. Merit sees continued opportunities for margin improvement, though not at the same rapid pace as in recent years, and remains optimistic about its business despite normal seasonality.
Merit Medical Systems, Inc. $MMSI Shares Purchased by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in Merit Medical Systems (MMSI) by 200.3% in the first quarter, now owning 17,612 shares valued at approximately $1.21 million. This comes as institutional investors collectively hold 99.66% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $100. Merit Medical also exceeded its recent quarterly earnings expectations, reporting $1.19 EPS against a $0.96 consensus and revenues of $418.84 million, a 9.5% increase year-over-year.
Merit Medical Systems, Inc. $MMSI Shares Sold by Bank of America Corp DE
Bank of America Corp DE reduced its stake in Merit Medical Systems (NASDAQ:MMSI) by 20.8% in the first quarter, selling 152,248 shares and retaining 580,918 shares valued at approximately $40 million. Institutional investors hold 99.66% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $100. Merit Medical exceeded quarterly earnings expectations, reporting $1.19 EPS against an estimated $0.96, and revenue of $418.84 million, a 9.5% increase year-over-year.
Merit Medical Systems, Inc. (MMSI) Stock Forecasts
Argus has raised its target price for Merit Medical Systems Inc. (MMSI) to $100.00, citing the company's role as a medical equipment developer and manufacturer. The report, published on August 12, 2026, highlights MMSI's products for interventional cardiology, radiology, and endoscopy procedures. Full access to the report is available through Yahoo Finance Silver.
Bank of America Forecasts Strong Price Appreciation for Merit Medical Systems (NASDAQ:MMSI) Stock
Bank of America has raised its price target for Merit Medical Systems (NASDAQ:MMSI) to $97 from $92, while maintaining a "neutral" rating, indicating a potential 6.36% upside. The company recently surpassed quarterly earnings expectations, reporting $1.19 EPS against a $0.96 consensus and revenue of $418.84 million, a 9.5% increase year-over-year. Institutional investors hold 99.66% of MMSI shares, and the stock has a "Moderate Buy" consensus rating from analysts with an average target price of $100.
MMSI Maintained by B of A Securities -- Price Target Raised to $97.00
B of A Securities maintained a neutral rating on Merit Medical Systems (MMSI) but raised its price target from $92.00 to $97.00. GuruFocus indicates MMSI is undervalued by 4.9% with a strong GF Score of 86/100, excelling in growth and valuation. While gurus show positive sentiment, insider sales suggest caution, presenting a mixed outlook for investors.
Merit Medical at Bank of America smid cap virtual conference: growth, margins
Merit Medical Systems (MMSI) recently participated in the Bank of America SMID Cap Virtual Conference, where CFO Raul Parra highlighted the company's transition towards stronger growth, wider margins, and a streamlined reporting structure. The company raised its 2024 organic constant-currency revenue growth outlook and discussed significant operating margin expansion since 2019. Merit Medical also outlined its strategic focus on existing end markets, tuck-in acquisitions, and the upcoming long-range plan, while addressing leadership changes and the active M&A landscape.
14-Day Rally Sends Merit Medical Systems Stock Up 25%
The article "14-Day Rally Sends Merit Medical Systems Stock Up 25%" indicates a significant recent increase in the stock value of Merit Medical Systems. However, the provided content is largely boilerplate and does not contain the actual article details regarding this rally. It primarily consists of navigation links, copyright information, and disclaimers about financial data and interactive models.
Merit Medical Systems Stock Climbs 25% On A 14-Day Winning Streak
Merit Medical Systems (MMSI) stock has experienced a significant surge, climbing 25% over a 14-day winning streak, adding $1.1 billion to its market value. While this momentum is notable, the article advises investors to look beyond the streak and evaluate fundamental support, noting the company's above-median revenue growth but below-median operating margin and higher price-to-earnings multiple compared to the S&P 500 median. It emphasizes that streaks eventually end and encourages a disciplined approach to investment decisions based on thorough analysis rather than just market momentum.
Merit Medical Systems (MMSI) Is Up 6.2% After Raising 2026 Outlook And Q2 Beat Expectations – Has The Bull Case Changed?
Merit Medical Systems (MMSI) saw its stock rise by 6.2% after reporting strong second-quarter 2026 results, including higher sales and net income, and subsequently raising its full-year 2026 revenue outlook. While the upgraded guidance supports stronger near-term earnings, the company still faces risks such as product recalls and reimbursement issues. The article explores how these developments impact Merit's investment narrative and fair value.
BofA raises Merit Medical stock price target on growth outlook
BofA Securities has increased its price target for Merit Medical Systems (NASDAQ:MMSI) to $97 from $92, while maintaining a Neutral rating, citing confidence in the company's growth and margin outlook for 2026 and beyond. The firm's decision is based on an increased 2027 earnings per share estimate and higher peer multiples. This adjustment follows Merit Medical's strong Q2 performance, which also led Canaccord and Needham to raise their price targets.
Assenagon Asset Management S.A. Sells 70,521 Shares of Merit Medical Systems, Inc. $MMSI
Assenagon Asset Management S.A. significantly reduced its stake in Merit Medical Systems (NASDAQ:MMSI) by selling 70,521 shares, lowering its holdings by 34.2%. Despite this reduction, institutional investors collectively own 99.66% of the company, which recently reported strong quarterly earnings exceeding expectations and issued positive fiscal 2026 EPS guidance. Analysts maintain a "Moderate Buy" rating with an average price target above the current stock price.
Merit Medical Systems Stock Climbs 25% On A 13-Day Winning Streak
Merit Medical Systems (MMSI) stock has surged 25% over 13 consecutive trading days, adding $1.1 billion to its market value and bringing its total valuation to $5.4 billion. This impressive streak significantly outperforms the S&P 500's 4.3% gain over the same period, suggesting company-specific momentum driven by revenue growth of 10.2% over the last twelve months. Investors are prompted to re-evaluate the company's fundamentals, including its P/E multiple of 37.4, to determine if the current price is justified.
Why Merit Medical Systems (MMSI) Is Up 14.4% After Raising 2026 Revenue Outlook And Margins
Merit Medical Systems (MMSI) saw its stock rise by 14.4% after reporting strong Q2 2026 results and raising its full-year 2026 revenue outlook to US$1.631 billion–US$1.643 billion. This positive revision is attributed to better-than-expected first-half performance, recent acquisitions, and efficiency gains. While the raised guidance supports the company's near-term growth and profitability, investors are still weighing potential risks like WRAPSODY reimbursement delays and ongoing tariff pressures.
Merit Medical Systems (NASDAQ:MMSI) Earns "Buy" Rating from BTIG Research
BTIG Research has reaffirmed its "Buy" rating for Merit Medical Systems (NASDAQ:MMSI), setting a price target of $105, which suggests a 17% upside. The company recently surpassed earnings estimates with an EPS of $1.19 and saw its revenue increase by 9.5% year-over-year to $418.84 million. Merit Medical Systems currently holds a "Moderate Buy" consensus rating from analysts, with institutional investors owning nearly all of its stock.
Gradient Investments LLC Buys Shares of 23,890 Merit Medical Systems, Inc. $MMSI
Gradient Investments LLC has acquired 23,890 shares of Merit Medical Systems, Inc. (NASDAQ:MMSI), valued at approximately $1.66 million, contributing to the significant institutional ownership of 99.66% in the company. Merit Medical Systems recently reported strong quarterly earnings, beating analyst estimates with an EPS of $1.19 and a 9.5% revenue increase, and provided optimistic fiscal 2026 EPS guidance. Analysts maintain a "Moderate Buy" consensus rating for MMSI, with an average price target of $100.30, suggesting potential upside from its current share price.
First Trust Advisors LP Has $2.48 Million Position in Merit Medical Systems, Inc. $MMSI
First Trust Advisors LP significantly increased its stake in Merit Medical Systems, Inc. (MMSI) by 479.1% in the first quarter, now holding 35,907 shares valued at $2.48 million. Institutional investors collectively own 99.66% of MMSI, and analysts have a "Moderate Buy" consensus with an average price target of $100.30. Merit Medical reported strong quarterly earnings of $1.19 EPS, beating estimates, and revenue grew 9.5% year-over-year.
Merit Medical Systems, Inc. (NASDAQ:MMSI) Given Average Recommendation of "Moderate Buy" by Brokerages
Merit Medical Systems, Inc. (NASDAQ:MMSI) has received a consensus "Moderate Buy" rating from brokerages, with eight out of eleven analysts recommending a buy and three suggesting a hold. The average 12-month price target is $100.30, exceeding its opening price of $89.04. The company recently surpassed quarterly earnings and revenue expectations, reporting $1.19 EPS against an estimated $0.96, and revenue of $418.84 million against an estimated $405.25 million, representing a 9.5% year-over-year increase.
Merit Medical Systems Chief Operating Officer Neil Peterson Sells 68% Of Holding
Merit Medical Systems' Chief Operating Officer, Neil Peterson, recently sold 68% of his holdings, netting US$1.8m. This significant sale, along with other insider selling activities totaling US$7.3m over the last year, raises some concerns despite the company's profitability and strong insider ownership. While high insider ownership is positive, the consistent selling suggests caution.
Merit Medical Systems (MMSI) COO Neil Peterson Sells 21,449 Shares
Merit Medical Systems (MMSI) COO Neil Peterson sold 21,449 shares of the company for approximately $1.82 million, reducing his direct ownership to 25,551 shares. This sale is part of a broader insider selling trend, with 9 insider sells versus 5 buys over the past year. Despite this, the company is considered "Fairly Valued" by GuruFocus with a GF Value of $95.76, and all 6 tracked institutional gurus have increased their holdings, suggesting a divergence in sentiment between insiders and institutional investors.
Merit Medical to Participate in Upcoming Investors Conferences in August
Merit Medical Systems, Inc. announced its participation in two investor conferences in August 2026. Management will hold fireside chats at the Canaccord Genuity 46th Annual Growth Conference and the Bank of America SMID Cap Conference. Live audio webcasts and replays will be available on the company's investor relations website.
Merit Medical Systems Inc (MMSI) COO sells 21,449 shares at $85
Merit Medical Systems Inc. COO Neil W. Peterson sold 21,449 shares of common stock at $85.00 per share on August 4, 2026. Following this transaction, Peterson directly holds 25,551 common shares and non-qualified stock options for an additional 38,576 shares at various exercise prices and vesting schedules. The sale generated $1.82 million and was reported via a Form 4 filing.
